Slow Age: Interventions to Slow Aging in Humans (SlowAge)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05593939|
Recruitment Status : Completed
First Posted : October 26, 2022
Last Update Posted : April 25, 2023
The proportion of older individuals is growing, and it is therefore important to investigate ways to promote healthy aging. Exercise is one of the most studied interventions and is known to have a variety of health benefits. Dietary interventions have also shown encouraging results, with intermittent fasting being a promising anti-aging intervention. Likewise, dietary supplementation with precursors that can increase the central metabolite nicotinamide dinucleotide (NAD+) has powerful effects on aging at least in model organisms. Although physical exercise is known to increase health-span, the effects of these latter dietary interventions on aging lacks evidence in humans.
This is a randomized, controlled trial of interventions to slow aging in humans. Healthy older individuals will be randomized into either an aerobic exercise (EXE), time-restricted feeding (TRF), nicotinamide riboside (NR), or control group and followed for twelve weeks. Changes in biomarkers of aging will be assessed before and after the intervention. It is hypothesized that the interventions provide similar, superior benefits to these markers when compared to placebo.
Primary Outcome: Interleukin-6 levels. Secondary Outcomes: CRP, TNF-α, NAD+, hematologic age, epigenetic age (DNA methylation), transcriptomic age (RNA-sequencing), functional age (handgrip strength, gait speed), body composition, vocal age, and photo age
|Condition or disease||Intervention/treatment||Phase|
|Aging||Behavioral: Exercise Behavioral: Time restricted feeding Dietary Supplement: Nicotinamide riboside||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Slow Age: a Randomized, Controlled Clinical Trial of Interventions to Slow Aging in Humans|
|Actual Study Start Date :||May 1, 2022|
|Actual Primary Completion Date :||December 21, 2022|
|Actual Study Completion Date :||December 21, 2022|
Experimental: Exercise arm
12 week aerobic exercise will be performed in agreement with current guidelines for exercise in older adults from the American College of Sports Medicine. A frequency of 5 days/week, totaling 150-300 min/week, performed at both moderate and vigorous intensities is chosen. This dose has a high level of evidence supporting positive effects on health- and life-span.
Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., ~60-90% heart rate (HR) max. Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., ~60-90% heart rate (HR) max. Exercise intensity and duration will gradually increase up until week 3 to habituate the participants to the exercise. The training modality will change to reduce the risk of injuries and may be impacted by individual preferences to increase adherence. The training can be performed individually or in groups of 4-6 participants, depending on the geographical locations of the participants home address, and on the current recruitment rate.
Experimental: Time restricted feeding
A 12 week fasting/feeding regiment of 16 hours fasting /8 hours feeding each day is chosen. This ratio has been shown to be tolerable in older individuals.
Behavioral: Time restricted feeding
Participants randomized to the time restricted feeding group will be instructed to abstain from any caloric intake during the targeted fasting window of 16 continuous hours and consume ad libitum during the eating window of 8 hours.
Experimental: Nicotinamide riboside
Previous clinical trials have shown that an nicotinamide riboside dose up to 2 g/day is well tolerated with no treatment-emergent adverse events reported so far and with efficacy on our primary outcome measurement. A dose of 2 g/day NR is therefore chosen and will be split in two: 1 g in the morning and 1 g in the evening.
Dietary Supplement: Nicotinamide riboside
Participants randomized to the NR group will be instructed to take the administered tablets once in the morning (1 g) and once in the evening (1 g), in both cases with a meal.
No Intervention: Control
A control group with no intervention.
- Interleukin-6 levels in plasma [ Time Frame: Day 1 compared to day 84 ]
- Concentration of CRP in plasma [ Time Frame: Day 1 compared to day 84 ]
- Concentration of TNF-α in plasma [ Time Frame: Day 1 compared to day 84 ]
- Concentration of NAD in whole blood [ Time Frame: Day 1 compared to day 84 ]
- Change in fat mass [ Time Frame: Day 1 compared to day 84 ]Measured using bio-impedance
- Change in lean mass [ Time Frame: Day 1 compared to day 84 ]Measured using bio-impedance
- Grip strength [ Time Frame: Day 1 compared to day 84 ]
- Gait speed [ Time Frame: Day 1 compared to day 84 ]Measured over 4 meters.
- Predicted age (DNA methylation) [ Time Frame: Day 1 compared to day 84 ]From PBMCs
- Predicted age (Blood age) [ Time Frame: Day 1 compared to day 84 ]From 33 blood parameters
- Predicted age (Transcriptomics) [ Time Frame: Day 1 compared to day 84 ]From RNA seq of PBMCs
- Predicted age (voice) [ Time Frame: Day 1 compared to day 84 ]From voice recordings
- Predicted age (photo) [ Time Frame: Day 1 compared to day 84 ]From a portrait photo
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05593939
|University of Copenhagen|
|Copenhagen, Denmark, 2200|